A Phase 2/3 interventional study of Insulin Tregopil and Insulin Aspart in Type2 Diabetes Mellitus, sponsored by Biocon Limited. Completed at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-05-15.
Sponsored by Biocon Limited · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 403 studies in Diabetes Mellitus, Type 2 with a site in India — 33 open to participants now, 38 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · India.
Among the 403 studies in Diabetes Mellitus, Type 2 with a site in India, this one is the 278th largest by enrollment of the 342 interventional ones that give a count, is one of 16 that started in 2017, is one of 11 in phase 2/3, and was the 277th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →33 of the 403 studies in Diabetes Mellitus, Type 2 with a site in India are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in India, United States, Australia and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in India, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in India, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in India, United States, Argentina and 7 more countries
Ages 10–18
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
403 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 40 · Phase 3 211 · Phase 4 45
First in 2002; this study’s year is marked. 16 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 463 across the 342 interventional studies, 1,500 across the 57 observational. Of the 346 that completed or were terminated, 181 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
331 of 403 have an industry lead sponsor. The 10 most frequent:
Biocon Limited is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.
Biocon Limited has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
10 of the studies in Diabetes Mellitus, Type 2 with a site in India that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT06763146BayerAn Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice | 2026-11-30 |
| NCT07350967iIDEAS Group Holdings LimitedMagnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel Endoscopic Magnetic Metabolic Interventional Therapy | 2026-11-30 |
| NCT07549373Sharda UniversityEffect of Diode Laser, Gudmar and Vinegar in Diabetic Patients During Root Canal Treatment | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 403 studies in Diabetes Mellitus, Type 2 with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label Phase II/III study to evaluate the efficacy and safety of test drug, Insulin Tregopil (IN-105) compared with Insulin Aspart (IAsp) in Type 2 Diabetes Mellitus patients. on stable dose of Metformin and insulin Glargine. The study will be conducted in 2 parts, Part I and Part II. The study duration will be approximately 37 weeks for Part I and for Part II of the study respectively
Part I of the study is a Phase II multi-center, randomized, open label clinical study to evaluate the efficacy and safety of Insulin Tregopil (2 dose levels: 30 mg, 45 mg) compared with IAsp in the treatment of T2DM patients. Part II of the study is the Phase III, multi-center, randomized, open label clinical study to evaluate the efficacy and safety of Insulin Tregopil (30 mg or 45 mg based upon the outcome of Part I data) compared with IAsp in the treatment of T2DM patients. For Part I and Part II, the study duration will be approximately 37 weeks (3 weeks Screening, 8 weeks Run-in, 24 weeks Treatment, 2 weeks Safety follow-up). An Independent Data and Safety Monitoring Board (DSMB) will evaluate the data from Part I of the study. Part II of the study will be initiated after approval from the office of Drugs Controller General of India (DCGI) and Data Safety Monitoring Board (DSMB) recommendation based on review of data from Part I of the study. In both Part I and Part II of the study, T2DM patients with glycated hemoglobin (HbA1c) 7.5 to 10% (both inclusive), on stable dose of metformin ± oral antidiabetic drugs (OADs) ± basal insulin who are eligible for insulin glargine administration as per investigator discretion and who satisfy the selection criteria will be enrolled. The eligible patients will go through a Run-in period of 8 weeks. At the end of 8 weeks Run-in period, eligibility will be checked and patients will enter the treatment period of 24 weeks and will be allocated to 3 treatment arms (Part I) or randomized to 2 treatment arms (Part II); if found eligible for randomization. A total of 90 patients in part 1 and 268 patients in part 2 will be randomised to the treatment arms from approximately 40 centers in India.
Key Inclusion Criteria
Key Exclusion Criteria
Patients with the following secondary complications of diabetes:
i. Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy (by the investigator, site ophthalmologist or an optometrist; as per standard site practice) within 6 months prior to Screening. ii. Renal dysfunction indicated by modification of diet in renal disease estimated \< 45 mL/min/1.73 m2 and/or diabetic nephropathy and/or clinical nephrotic syndrome at Screening. iii. History or presence of severe form of neuropathy or signs and symptoms of severe cardiac autonomic neuropathy. iv. Patients with non-traumatic amputation (at any time) or clinically significant
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Strength of each tablet is 15mg
Drug: Insulin Tregopil
Strength of each tablet is 15mg
Drug: Insulin Tregopil
Pre-filled pen: 100 U/L
Drug: Insulin Aspart
Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
Also known as: IN-105
Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
Change From Baseline in HbA1c at 24 Weeks (Part 1)
The primary endpoint is change from baseline in HbA1c after 24 weeks of randomized treatment.
Time frame: Week 0, Week 24
Change From Baseline in HbA1c at Week 12 (Part 1)
This secondary outcome is the change from baseline in HbA1c after 12 weeks of randomized treatment. For this endpoint baseline (Week 0) and Week 12 have been presented.
Time frame: Week 0, Week 12
Participants Achieving HbA1c < 7% (Part 1)
Number of participants achieving HbA1c \< 7% at Week 12 and Week 24.
Time frame: Week 12, Week 24
Percentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1)
A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\]
Time frame: Week 0 through Week 24
Weight (Kgs) (Part 1)
Change from Baseline in weight (kgs) to 24 weeks
Time frame: Week 0 and Week 24
Lipid Profile (Part 1)
Change from Baseline in lipid profile (triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol) to 24 weeks
Time frame: 24 weeks
Post-prandial Glucose (PPG) Excursion (Part 1)
Change from Baseline in the mean 60, 90, 120 minutes PPG excursions assessed from standardized test meal at Week 24.
Time frame: Week 0, Week 24
Number of Participants With Treatment-Emergent Adverse Events (Part 1)
Includes participants who have experienced at least one treatment emergent adverse events over 24 weeks
Time frame: 24 weeks
Anti-drug Antibody Levels
Incidence and change from baseline in the relative levels of anti-drug antibody levels over 24 weeks
Time frame: 24 weeks
CGM
Area under the glucose curve below 70 mg/dL derived from CGM, applicable for only part II study
Time frame: 24 weeks
Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24
Number of participants achieving HbA1c \< 7% at Week 12 and Week 24 without reported clinically significant or severe hypoglycemic events between end of Week 8 and Week 24.
Time frame: Week 12, Week 24
Out of 20 sites, which were selected for recruitment, 19 sites enrolled subjects in the run-in period, of which 15 sites later assigned subjects to randomized treatment: India:20 sites
| Milestone | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Started | 31 | 30 | 30 |
| Exposed | 31 | 30 | 30 |
| Completed | 29 | 27 | 29 |
| Not completed | 2 | 3 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Rescue criteria | 1 | 1 | 0 |
| Withdrew: Voluntary withdrawal of consent | 1 | 1 | 1 |
The primary endpoint is change from baseline in HbA1c after 24 weeks of randomized treatment.
| Percentage of glycosylated hemoglobin | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Baseline (Week 0) | 8.23 ± 0.577 | 8.10 ± 0.670 | 8.07 ± 0.697 |
| Week 24 | 8.38 ± 1.139 | 8.21 ± 0.969 | 7.29 ± 0.788 |
This secondary outcome is the change from baseline in HbA1c after 12 weeks of randomized treatment. For this endpoint baseline (Week 0) and Week 12 have been presented.
| Percentage of glycosylated haemoglobin | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Baseline (Week 0) | 8.23 ± 0.577 | 8.10 ± 0.670 | 8.07 ± 0.697 |
| Week 12 | 8.04 ± 0.940 | 8.01 ± 0.898 | 7.18 ± 0.810 |
| Change from Baseline | -0.17 ± 0.913 | -0.07 ± 0.866 | -0.88 ± 0.850 |
Number of participants achieving HbA1c \< 7% at Week 12 and Week 24.
| Participants | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Week 12 | 4 | 3 | 13 |
| Week 24 | 2 | 2 | 10 |
A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\]
| Participants | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Percentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1) | 26 | 26 | 25 |
Change from Baseline in weight (kgs) to 24 weeks
| Kg | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Baseline (Week 0) | 68.54 ± 11.559 | 68.88 ± 9.040 | 67.76 ± 9.628 |
| Week24 | 68.98 ± 11.837 | 70.15 ± 8.915 | 68.47 ± 9.761 |
| Change from Baseline | 0.93 ± 1.212 | 0.30 ± 1.955 | 0.66 ± 1.807 |
Change from Baseline in lipid profile (triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol) to 24 weeks
No measurements were reported for this outcome.
Change from Baseline in the mean 60, 90, 120 minutes PPG excursions assessed from standardized test meal at Week 24.
| mg/dL | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Week 0, 60 min | 79.5 ± 45.53 | 98.3 ± 41.94 | 74.4 ± 42.85 |
| Week 0, 90 min | 92.4 ± 47.94 | 106.4 ± 35.39 | 90.8 ± 35.35 |
| Week 0, 120 min | 100.9 ± 58.18 | 113.5 ± 53.45 | 93.7 ± 41.20 |
| Week 24, 60 min | 35.8 ± 44.26 | 32.7 ± 45.13 | 55.1 ± 34.57 |
| Week 24, 90 min | 53.8 ± 45.38 | 47.2 ± 44.84 | 66.3 ± 36.13 |
| Week 24, 120 min | 64.1 ± 51.87 | 50.2 ± 44.23 | 65.5 ± 34.58 |
Includes participants who have experienced at least one treatment emergent adverse events over 24 weeks
| Participants | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (Part 1) | 5 | 6 | 4 |
Incidence and change from baseline in the relative levels of anti-drug antibody levels over 24 weeks
No measurements were reported for this outcome.
Area under the glucose curve below 70 mg/dL derived from CGM, applicable for only part II study
No measurements were reported for this outcome.
Number of participants achieving HbA1c \< 7% at Week 12 and Week 24 without reported clinically significant or severe hypoglycemic events between end of Week 8 and Week 24.
| Participants | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| Week 12 | 4 | 3 | 11 |
| Week 24 | 1 | 3 | 7 |
Collected over From the date on or after first day of exposure to randomized treatment until the last day of randomized treatment, an average of 24 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Tregopil (IN-105) - 45mg | 0/31 (0%) | 0/31 (0%) | 5/31 (16.1%) |
| Insulin Tregopil (IN-105) - 30mg | 0/30 (0%) | 0/30 (0%) | 5/30 (16.7%) |
| Insulin Aspart | 0/30 (0%) | 0/30 (0%) | 4/30 (13.3%) |
| Event | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart |
|---|---|---|---|
| GastritisGastrointestinal disorders | 1/31 | 1/30 | 0/30 |
| NauseaGastrointestinal disorders | 0/31 | 0/30 | 1/30 |
| PyrexiaGeneral disorders | 1/31 | 1/30 | 0/30 |
| Urinary tract infectionInfections and infestations | 0/31 | 1/30 | 0/30 |
| DysenteryInfections and infestations | 0/31 | 1/30 | 0/30 |
| Upper respiratory tract infectionInfections and infestations | 0/31 | 1/30 | 0/30 |
| FallInjury, poisoning and procedural complications | 0/31 | 0/30 | 1/30 |
| Vulval lacerationInjury, poisoning and procedural complications | 0/31 | 0/30 | 1/30 |
| Hepatic enzyme increasedInvestigations | 0/31 | 1/30 | 0/30 |
| Decreased appetiteMetabolism and nutrition disorders | 0/31 | 0/30 | 1/30 |
Safety Analysis Set included all randomized subjects.
| Age, Continuous(Year) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| Mean | 52.1 ± 9.49 | 50.9 ± 9.44 | 54.5 ± 8.18 | 52.5 ± 9.08 |
| Sex: Female, Male(Participants) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| Female | 15 | 14 | 14 | 43 |
| Male | 16 | 16 | 16 | 48 |
| Race (NIH/OMB)(Participants) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 31 | 30 | 30 | 91 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| India | 31 | 30 | 30 | 91 |
| Weight(kg) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| Mean | 68.54 ± 11.559 | 68.88 ± 9.040 | 67.76 ± 9.628 | 68.39 ± 10.048 |
| Height(cm) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| Mean | 158.84 ± 7.987 | 158.76 ± 9.268 | 158.20 ± 9.321 | 158.60 ± 8.776 |
| BMI(kg/m^2) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| Mean | 27.13 ± 3.866 | 27.39 ± 3.418 | 27.13 ± 3.667 | 27.22 ± 3.618 |
| Duration of T2DM(years) | Insulin Tregopil (IN-105) - 45mg | Insulin Tregopil (IN-105) - 30mg | Insulin Aspart | Total |
|---|---|---|---|---|
| Mean | 8.78 ± 7.867 | 7.83 ± 7.715 | 8.12 ± 6.788 | 8.25 ± 7.404 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Feb 2019, 13 months.
Results were first posted in May 2020, 1 year 3 months after primary completion.
Of 32 phase 2/3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin tregopil
Biocon Limited